The Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) advanced 1.25% and 1.32%, respectively, in Q3 ...
Hosted on MSN25d
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transitionEarnings Call Insights: Takeda Pharmaceutical ... sale of Takeda Teva. Takeda raised its full-year 2024 guidance, projecting JPY 4.59 trillion in revenue, JPY 1.15 trillion in core operating ...
multiple pharmaceutical agents applied could be reported. The full survey questionnaire can be found in the supplementary materials. Descriptive statistical analysis was performed with Microsoft Excel ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...
In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...
In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $21.00. The company’s shares closed ...
Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.78.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback